Methodology
robust evidence
4 min · 3 sources
Published Jun 23, 2026

Minimum Clinically Important Difference (MCID)

The smallest change in a score that people actually notice.

It helps you avoid buying into study results that are real on paper but too small to matter in daily life.

Also known as MCID · MID · minimal important difference · minimally important difference · clinically meaningful change · meaningful within-patient change · minimal clinically important difference

MCID marks the boundary between a statistically detectable change and a change people actually feel ¹.
The threshold belongs to a specific scale, condition, and population, not to all studies or all patients ².
A statistically significant result can still fall below the MCID and remain too small to matter ¹.

The study result that can be true and still feel pointless

A trial can report a “statistically significant” improvement in pain, sleep, or fatigue and still leave most people saying, “I do not feel different.” That is the exact problem MCID was built to solve. The term became widely used after Jaeschke, Singer, and Guyatt described it as the smallest difference in a health score that patients perceive as beneficial and that would justify a change in management, assuming side effects and costs are acceptable.

The surprise is this: MCID is not a magic number built into a questionnaire. It is a judgment about what size of change matters in a specific setting. A 2-point improvement may matter on one pain scale, while a 2-point improvement on another scale may be meaningless. The number depends on the tool, the condition, the starting severity, the population, and whether you are looking at one person or the average of a group.

What MCID measures

Minimum Clinically Important Difference asks a practical question: “How much does the score need to move before the change is worth caring about?” If a sleep supplement trial uses a 100-point sleep-quality score and the average score improves by 3 points, that may be statistically detectable if the study is large. But if the MCID for that scale is 8 points, the average improvement is probably too small for most users to notice.

This is why MCID is different from a p-value. A p-value asks whether the result is likely to be due to chance. MCID asks whether the size of the result has practical meaning. Both matter, but they answer different questions.

Researchers estimate MCID in two main ways. The stronger approach anchors the score change to something people can understand, such as a patient saying they feel “a little better” or “much better.” This is called an anchor-based method because the number is tied to a real-world judgment. A weaker but common approach uses the spread of scores in the dataset, such as half a standard deviation. That can help, but it does not prove patients felt better.

The supplement-reader decision

Use MCID as a filter before you trust a headline. If a supplement study reports a significant improvement on a symptom questionnaire, look for the actual size of the change and compare it with the MCID for that exact scale. If the change is below the MCID, the honest takeaway is not “it works.” The better takeaway is: “The study detected a small movement, but it may be below the level most people would feel.”

Regulators care about this distinction too. The U.S. Food and Drug Administration guidance on patient-reported outcome measures says trial results should support claims of treatment benefit, not merely show movement on a questionnaire. In plain terms, a score change needs a human meaning before it becomes a convincing benefit claim.

Deep dive

How it works

MCID can be estimated for change within one person or for differences between groups. These are related but not identical. A within-person threshold asks how much one patient must improve before the change feels meaningful. A between-group threshold asks how large the average advantage of one treatment over another must be before the trial result matters in practice. Confusing those two versions can make a treatment look more or less impressive than it really is.

When you'll see this

The term in the wild

You read a melatonin study that reports a statistically significant improvement on a sleep-quality questionnaire.

Do not stop at the p-value. Find the point change and ask whether it reaches the MCID for that exact sleep scale.

This can separate a detectable sleep-score shift from a change a tired person would actually notice.
A glucosamine trial reports a small improvement in knee pain compared with placebo.

Pain scales often have MCID thresholds. If the average improvement is below that threshold, the result may be too small to guide a buying decision.

You avoid paying for a product based only on a tiny average difference.
A clinical paper reports that a treatment improved a patient-reported fatigue score by 4 points.

That number means little by itself. It becomes meaningful only when compared with the known MCID for that fatigue instrument and population.

You can tell whether the paper is describing a real-life improvement or only a score movement.

Myths vs reality

What people get wrong

Myth

If a result is statistically significant, it must be clinically important.

Why people believe it Research abstracts often lead with p-values because journals and trial reports have long treated them as proof that something happened. MCID asks the next question, which is whether the thing that happened is big enough to matter.

Reality

Statistical significance means the result is unlikely to be random under the study’s assumptions. It does not tell you whether the change is large enough to feel or matter.
Myth

Every questionnaire has one fixed MCID forever.

Why people believe it The abbreviation MCID sounds as if it names a built-in property of a scale. Revicki and colleagues specifically warned that a minimally important difference is not an unchanging feature of an instrument.

Reality

The same questionnaire can have different meaningful-change thresholds in different groups. A mild-symptom group, a severe-symptom group, and a post-surgery group may not experience the same point change the same way.
Myth

MCID proves that a treatment works for every individual patient.

Why people believe it Trial summaries usually report averages because averages are compact. They can hide the spread of individual responses.

Reality

A group average can reach the MCID while some people improve a lot, some improve a little, and some do not improve at all.
Myth

A company can claim meaningful benefit just because a questionnaire score moved.

Why people believe it The named cause is the marketing shortcut around patient-reported outcome scores. FDA’s 2009 PRO guidance was written partly to make outcome claims depend on well-defined, interpretable measures.

Reality

For patient-reported outcomes, a benefit claim needs evidence that the score change has a clear patient meaning, not only a numerical difference.

A common failure mode is comparing a study’s result with an MCID from a different scale. A 3-point change on one pain questionnaire cannot be judged using the MCID from another pain questionnaire. Match the scale name, score range, condition, and population before deciding whether the result matters.

Frequently asked

Common questions

Where do I usually find MCID in a paper?

Look in the methods section, the outcome-measure description, or the discussion. It may be written as MCID, MID, minimal important difference, or clinically meaningful change.

What if a study does not report the MCID?

Treat the result as harder to interpret. You can still read the direction and size of the effect, but you should be cautious about calling it meaningful without a threshold tied to that scale.

Can MCID be used for blood markers?

Sometimes, but it is most natural for symptom scores and quality-of-life scores. For blood markers, clinical meaning often depends on risk ranges, diagnosis thresholds, or whether the change alters care.

Is a result below the MCID always useless?

Not always. A small average change might still matter if the supplement is cheap, low risk, and some people respond strongly. But it should not be presented as a clear, broadly noticeable benefit.

Why do some papers use MID instead of MCID?

Many researchers prefer MID because the word “clinical” can imply a doctor-centered judgment. MID keeps the focus on the smallest important difference, often from the patient’s point of view.

Sources